SP Manipulation, page-60

I do remember MM being interviewed on a radio program where she highlighted the frustrations she has in regards to the lack of understanding of shareholders and the general community as to how long the process is to complete trials from beginning to end, collect data, analyse date, release data.
While I'm certainly no expert, I would assume the red tape associated with these trials would be more than most of us would understand.
On top of this, the timeframe would be longer than most when you're a company who has nearly always had minimal funds, as Biotron has had.
Don't get me wrong, I get as frustrated as the next person, but they're not building a house here. They're trying to prove a drug's effectiveness in the fight against one of mankind's most elusive and devastating viruses we've seen.
The risk vs reward here is worth it IMO